February 11, 2004
Thirty-six subjects with multiple-PI experience entered the study, and were randomized to one of two treatment arms: 1) high-dose lopinavir/ritonavir at five capsules (667 mg/167 mg) twice daily, or 2) standard-dose lopinavir/ritonavir at three capsules twice daily with an additional 200-mg twice-daily dose of ritonavir. Plasma samples for lopinavir concentrations were obtained at week three. The study lasted 48 weeks.
At week three, both dosing schemes produced substantially higher lopinavir levels than observed with data from prior studies with standard-dose lopinavir. The use of the five-capsule, twice-daily lopinavir/ritonavir achieved lopinavir trough levels that were 73% higher, while the extra ritonavir strategy achieved trough levels that were 56% higher. The former was also generally better tolerated, with lower rates of diarrhea. Virologic suppression to less than 400 copies was achieved in 64% of the patients in the high-dose lopinavir/ritonavir group versus 58% in the extra-ritonavir group, and 83% of the study subjects overall experienced at least a 1 log HIV RNA reduction. In a multivariate analysis evaluating the predictors of virologic response, both the lopinavir/ritonavir IQ and the number of active nucleosides were independently associated with better viral load reduction.
This study confirms that the baseline resistance profile and drug plasma levels provided by the IQ add additional information about the likelihood of treatment response. It furthermore raises the question of whether therapeutic drug monitoring and subsequent dose manipulation should be introduced into clinical practice, a concept currently being explored in an ACTG study. The finding that baseline NRTI activity also predicted the magnitude of the HIV RNA response was a reminder that in treatment-experienced patients, it is critical to maximize the activity of all components of the regimen whenever possible.
Abstract: Lopinavir Inhibitory Quotient Predicts Virologic Response in Highly Antiretroviral-Experienced Patients Receiving High-Dose Lopinavir/Ritonavir (Oral 134)
Authored by: R. Bertz, J. Li, M. King, D. Kempf, D. Podzamczer, C. Flexner, C. Katlama, D. V. Havlir, S. Letendre, J. Eron, L. Weiss, J. Gatell, A. Simon, K. Robinson, S. Brun
Affiliations: Abbott Labs., Abbott Park, IL; Hosp. de Bellvitge, Barcelona, Spain; Johns Hopkins Univ. Sch. of Med., Baltimore, MD; Hosp. de la Pitie-Salpetriere, Paris, France; Univ. of California, San Francisco, CA; Univ. of California, San Diego, CA; Univ. of North Carolina at Chapel Hill, NC; Hosp. Europeen George Pompidou, Paris, France; Hosp. Clin., Barcelona, Spain
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|